Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT04929236 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT04929236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04929236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2023
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric chronic inflammatory demyelinating polyneuropathy